The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
Switching from finasteride to dutasteride involves gradually increasing dutasteride while decreasing finasteride. Studies show dutasteride 0.5 mg daily can improve hair density in men unresponsive to finasteride.
The conversation discusses improving a hair loss treatment stack without using Minoxidil. Microneedling is suggested, Alpecin is deemed ineffective, and there are concerns about the safety of Minoxidil compared to finasteride.